IP40
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
IP40 (IP40) - Total Liabilities
Latest total liabilities as of September 2025: €4.49 Million EUR
Based on the latest financial reports, IP40 (IP40) has total liabilities worth €4.49 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IP40 - Total Liabilities Trend (2021–2024)
This chart illustrates how IP40's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
IP40 Competitors by Total Liabilities
The table below lists competitors of IP40 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Matahari Putra Prima Tbk
JK:MPPA
|
Indonesia | Rp3.12 Trillion |
|
PYRAMID TECHNOPLAST ORD (BSE)
NSE:PYRAMID
|
India | ₹2.26 Billion |
|
Little Green Pharma Ltd
AU:LGP
|
Australia | AU$11.59 Million |
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
Germany | €29.69 Million |
|
Akdeniz Yatirim Holding AS
IS:AKYHO
|
Turkey | TL112.52 Million |
|
Bersama Zatta Jaya
JK:ZATA
|
Indonesia | Rp157.25 Billion |
|
Canfor Pulp Products Inc
PINK:CFPUF
|
USA | $267.20 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down IP40's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IP40's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IP40 (2021–2024)
The table below shows the annual total liabilities of IP40 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €2.24 Million | -12.37% |
| 2023-12-31 | €2.55 Million | +240.08% |
| 2022-12-31 | €751.00K | -78.93% |
| 2021-12-31 | €3.56 Million | -- |